In that study, the combination of GLP-1R therapy and insulin predicted a greater risk for pancreatic cancer compared with GLP-1R monotherapy, consistent with a reported tumor-promoting role of insulin in preclinical pancreatic cancer models (54–56). Here, INS is linked to neoplasm.